Clinical trial
Retention Rate of Acalabrutinib in a Non-interventional Setting
NCT05645172 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Retention Rate of Acalabrutinib in a Non-interventional Setting
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- December 12, 2022
- Completion date
- October 15, 2026
- Enrollment
- 137 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukaemia (cll)